Accordingly, leukemic cells carrying the BCR–ABL, MLL–AF9 fusion proteins, and co-expressing HoxA9 and Meis1 were all affected by the inactivation of Pml in MSCs, thus suggesting the possibility that the same therapeutic intervention could be beneficial in multiple leukemia sub-types. This evidence concerns the gene MEIS1 and leukemia.